Related Experiment Video
Updated: Jan 21, 2026

Isolation of High-density Lipoproteins for Non-coding Small RNA Quantification
Published on: November 28, 2016
High-Density Lipoprotein in Lupus: Disease Biomarkers and Potential Therapeutic Strategy
Sang Yeop Kim1, Minzhi Yu1, Emily E Morin1
1University of Michigan, Ann Arbor.
Insights
Systemic lupus erythematosus (SLE) patients develop dysfunctional high-density lipoproteins (HDLs) that accelerate atherosclerosis. These altered HDLs promote inflammation and cardiovascular disease (CVD), suggesting HDL-targeted therapies for lupus patients.
Area of Science:
- Cardiovascular Science
- Immunology
- Lipid Metabolism
Background:
- Systemic lupus erythematosus (SLE) is linked to accelerated atherosclerosis and cardiovascular disease (CVD).
- Traditional risk factors do not fully explain the increased CVD risk in SLE patients.
- Altered high-density lipoproteins (HDLs) are implicated in the heightened atherosclerosis observed in SLE.
Purpose of the Study:
- To investigate the role of high-density lipoproteins (HDLs) in the accelerated atherosclerosis of Systemic lupus erythematosus (SLE).
- To characterize the functional and compositional changes in HDLs from SLE patients.
- To explore the potential of HDL-based therapies for cardiovascular complications in SLE.
Main Methods:
- Analysis of HDL composition, including proteomic and lipidomic signatures.
- Assessment of HDL function, such as cholesterol efflux capacity, antioxidant, and anti-inflammatory properties.
- Evaluation of HDL's role in promoting or inhibiting inflammation and atherogenesis in the context of SLE.
Main Results:
- SLE patients exhibit reduced levels of high-density lipoproteins (HDLs) with altered composition and function.
- Systemic inflammation, oxidative stress, and autoimmunity in SLE lead to dysfunctional, proinflammatory HDLs.
- These dysfunctional HDLs demonstrate impaired atheroprotective functions, including reduced cholesterol efflux and diminished anti-inflammatory and antioxidant capacities.
- Dysfunctional HDLs may actively promote atherogenesis by inducing vascular inflammation.
Conclusions:
- Dysfunctional high-density lipoproteins (HDLs) are a significant factor in accelerated atherosclerosis and cardiovascular disease (CVD) in Systemic lupus erythematosus (SLE) patients.
- Altered HDLs in SLE possess proinflammatory properties and impaired atheroprotective functions.
- Dysfunctional HDLs represent a potential biomarker for atherosclerosis in SLE and suggest HDL-targeted therapies, such as reconstituted HDLs, as a promising treatment strategy for CVD in this population.
Abstract:
Systemic lupus erythematosus (SLE) patients exhibit accelerated development of atherosclerosis and increased incidents of cardiovascular disease (CVD) that cannot be explained by traditional risk factors alone. Accumulating evidence suggests that reduced levels of high-density lipoproteins (HDLs), along with altered HDL composition and function, may contribute to the accelerated atherosclerosis in SLE patients. Normally, HDLs play various atheroprotective roles through facilitating cholesterol efflux, inhibiting vascular inflammation, and scavenging oxidative species. However, systemic inflammation, oxidative stress, and autoimmunity in SLE patients induce changes in HDL size distribution and proteomic and lipidomic signatures. These compositional changes in HDLs result in the formation of proinflammatory, dysfunctional HDL. These lupus-altered HDLs have impaired antiatherogenic function with reduced cholesterol efflux capacities, impaired antioxidation abilities, and diminished antiinflammatory properties. In fact, dysfunctional HDL may promote atherogenesis by inducing inflammation. Thus, dysfunctional HDLs could be an important biomarker of accelerated atherosclerosis in lupus. Additionally, HDL-targeted therapies, especially infusion of reconstituted HDLs, may serve as a potential therapeutic intervention for SLE patients with CVD.
More Related Videos
09:48Fast and Simplified Method for High Through-put Isolation of miRNA from Highly Purified High Density Lipoprotein
Published on: July 27, 2016
07:26Stimulation of Vascular Endothelial Cells Using Neutrophil Extracellular Traps in the Presence of Low-Density Lipoprotein
Published on: August 12, 2025
Related Concept Videos
Density
Therapeutic Index
Current Density
Potential Energy
Chemical bonds that form attractive forces between atoms also contain potential energy, called chemical energy. When a chemical reaction...
Standard Electrode Potentials
Therapeutic Communication
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...